J
John C. O'Connor
Researcher at DuPont
Publications - 39
Citations - 2857
John C. O'Connor is an academic researcher from DuPont. The author has contributed to research in topics: Prolactin & Estrogen. The author has an hindex of 23, co-authored 39 publications receiving 2727 citations.
Papers
More filters
Journal ArticleDOI
The toxicology of perfluorooctanoate.
Gerald L. Kennedy,John L. Butenhoff,Geary W. Olsen,John C. O'Connor,Andrew M. Seacat,Roger Perkins,Lisa B. Biegel,Sandra R. Murphy,David G. Farrar +8 more
TL;DR: The hepatocellular tumors observed in rats are likely to have been the result of the activation of the peroxisome proliferator activated receptor α (PPARα), and the proposed mechanism for Leydig-cell tumor formation is of questionable relevance to humans.
Journal ArticleDOI
Mechanisms of Extrahepatic Tumor Induction by Peroxisome Proliferators in Male CD Rats
TL;DR: It is suggested that estradiol may play a role in enhancement of Leydig cell tumors in the rat, and that peroxisome proliferators may induce tumors via a non-LH type mechanism.
Journal ArticleDOI
The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat
TL;DR: The potential reproductive toxicity of APFO across two generations of offspring was studied using current EPA OPPTS 870.3800 guidelines and Reproductive endpoints including mating, fertility, and natural delivery were not affected in either generation.
Journal ArticleDOI
Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO).
Scott E. Loveless,Carol Finlay,Nancy E. Everds,Steven R. Frame,Peter J. Gillies,John C. O'Connor,Charles R. Powley,Gerald L. Kennedy +7 more
TL;DR: In both rats and mice, the overall responses to the linear/branched and the linear forms of PFOA were similar, but the branched form appears to be less potent.
Journal ArticleDOI
Evaluation of a 15-Day Screening Assay Using Intact Male Rats for Identifying Antiandrogens
TL;DR: 5 of the six test substances were identified as endocrine-active substances consistent with their known/proposed mechanism(s) of action and increased relative liver weight, illustrating that the ability to identify EACs using the intact male assay will be equivalent regardless of the route of compound administration.